MENOPAUSE GUIDELINES

NICE GUIDELINES NG23
Menopause: Identification and Management –
NICE guidance recommends prescribers should:¹

• Practise individualised care, taking time to understand each person's lifestyle factors, treatment goals, and therapy preferences
• Consider using an FSH test only for people aged 40 to 45 who have menopausal symptoms (including a change in their menstrual cycle) or for those under 40 in whom menopause is suspected
• Offer HRT to manage vasomotor symptoms, after discussing the benefits and risks in the context of the individual's age, health and circumstances
• Consider HRT for depressive symptoms that emerge at the same time as other menopausal symptoms*
• Do not routinely offer selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs) or clonidine as first-line treatments for vasomotor symptoms alone
• Consider transdermal rather than oral HRT for people who are at increased risk of VTE, including those with a BMI over 30 kg/m²
• Provide reassurance that combined or oestrogen-only HRT does not increase the risk of CVD or mortality from CVD
• Explain to women that taking HRT is not associated with an increased risk of developing type 2 diabetes

*This information is taken from NICE guideline NG23. These recommendations apply to HRT as a treatment class and are not specific to Lenzetto®. Prescribers should consult individual SmPCs for more information on licensed indications. Lenzetto® is not indicated for the treatment of depressive symptoms.